On November 9, 2026, LifeMD, Inc. (the “Company”) and its subsidiaries LFMD Pharmacy Holdings, LLC, LFMD Pharmacy Holdings 1, LLC, and LFMD Pharmacy Services, LLC (collectively, the “Borrower”) entered into and closed on a Loan and Security Agreement with Avenue Venture Opportunities Fund II, L.P., as a lender and as administrative agent and collateral agent, and Avenue Growth Lending Fund III, L.P. (together with Avenue Venture Opportunities Fund II, L.P., the “Lenders”), and a Supplement to the Loan and Security Agreement (the “Supplement,” and together with the Loan and Security Agreement, the “Loan Agreement”), pursuant to which the Lenders made a loan to the Borrower in an aggregate principal amount of $12.5 million (the “Loan”), secured by a security interest in substantially all of the Borrower’s assets.
|
LifeMD, Inc. is a direct-to-patient healthcare company providing virtual medical care and pharmacy services through a vertically integrated platform. The company operates three consumer healthcare brands, with LifeMD serving as the flagship virtual primary care and specialty platform. Its services include urgent and chronic care, weight management, men's and women's health, hormone optimization, mental health, dermatology, and cardiology. LifeMD utilizes a proprietary technology platform that integrates a 50-state affiliated provider network, a nationwide pharmacy network, and a wholly-owned commercial pharmacy located in Lancaster, Pennsylvania. The company offers prescription and over-the-counter treatments, laboratory diagnostics, and wellness coaching via desktop and mobile applications. Since June 2024, LifeMD has accepted commercial and government health insurance for virtual primary care services, including obesity-related care. The company employs AI-enabled clinical and operational technologies to support diagnosis, treatment, prescription fulfillment, and ongoing care management. LifeMD serves patients across the United States, offering synchronous and asynchronous virtual consultations through licensed physicians and nurse practitioners. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Healthcare Plans | Homepage lifemd.com |
| Sector Healthcare | IR page ir.lifemd.com | |
|
Tags
telehealth, virtual primary care, weight management, men's health, women's health, hormone health, mental health, dermatology, cardiology, pharmacy services, subscription model, glp-1 medications, LifeMD, LifeMD+, Wegovy, Zepbound, metformin, bupropion, topiramate
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 139.942M |
| Market cap (USD) | $ 139.942M |
| P/E | 74.95 |
| PEG | — |
| P/BV | -241.42 |
| P/S | 0.95 |
| P/OCF | -13.07 |
| P/FCF | -12.48 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 62.0% |
| ROI | — |
| ROIC | — |
| Profit margin | 7.4% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 13 |
| Quality score | -26.7% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 194.055M | 212.454M | 152.547M | 119.034M | 92.876M | 37.294M | 83.553K | 42.515K | 5.055M | 5.239M | 1.219M | 714.158K | 808.363K | 673.778K |
| Net profit | 14.354M | -18.882M | -20.596M | -45.536M | -60.898M | -58.647M | -3.137M | -1.241M | -1.206M | -1.108M | -61.992K | -460.485K | -268.262K | -445.649K |
| Free cash flow | 6.41M | 16.022M | 8.616M | -23.302M | -33.333M | — | — | — | — | — | — | — | — | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (USD) | 444,743 | 398,770 | 99,053 | 97,448 | 648,421 | 980,055 | 2.83M | 5.28M | 8.22M | 9.31M |
| ↳ YoY growth | +188.0% | -10.3% | -75.2% | -1.6% | +565.4% | +51.1% | +189.2% | +86.2% | +55.7% | +13.2% |
| ↳ 5y CAGR | +65.0% | +51.7% | +5.0% | +45.4% | +33.2% | +17.1% | +48.0% | +121.5% | +142.8% | +70.4% |
| Lease liabilities (USD) | — | — | — | 29,978 | 285,323 | 1.79M | 1.33M | 677,029 | 6.77M | 6.32M |
| Cash and deposits (USD) | 182,561 | 141,379 | 180,093 | 1.11M | 9.18M | 41.3M | 3.96M | 33.1M | 35M | 36.8M |
| Intangible assets (USD) | — | — | 1.01M | 675,452 | 339,840 | 19,761 | 3.83M | 3.01M | 2.03M | 262,334 |
| Right-of-use assets (USD) | — | — | — | 23,625 | 274,437 | 1.75M | 1.21M | 594,897 | 6.4M | 5.27M |
| Cash flow detail | ||||||||||
| Operating cash flow (USD) | -407,914 | -817,216 | -905,518 | 251,408 | -12.1M | -33.1M | -22.9M | 8.82M | 17.5M | 8.28M |
| Purchases of property, plant and equipment (USD) | — | — | — | — | — | -247,365 | -366,633 | -203,814 | -1.49M | -1.87M |
| Purchases of intangible assets (USD) | — | — | -100,000 | — | — | -22,231 | -4M | -148,868 | -3,798 | — |
| Change in receivables (cash effect) (USD) | -361,443 | 95,092 | 29,137 | 1,605 | -550,973 | 17,702 | -2.19M | -2.44M | -2.94M | 1.15M |
| Change in inventories (cash effect) (USD) | -99,219 | -546,891 | -341,358 | 72,557 | -314,199 | -409,823 | -2.18M | 405,746 | -713,095 | 23,782 |
| Change in payables (cash effect) (USD) | — | — | — | — | — | -893,956 | 1.25M | 978,062 | 4.92M | 3.24M |
| Dividends paid (cash effect) (USD) | — | — | — | — | — | -871,476 | -3.11M | -3.11M | -3.11M | -3.11M |
| Share buybacks (cash effect) (USD) | — | -76,648 | — | — | — | — | — | — | — | -270,000 |
| Interest paid (cash effect) (USD) | -13,650 | -4,723 | -4,383 | -80,660 | -1.67M | -435,048 | -189,000 | -2.15M | -2.53M | -1.46M |
| Income taxes paid (cash effect) (USD) | — | — | — | — | — | — | — | — | -214,211 | -587,000 |
| Share-based compensation (USD) | 587,991 | 162,741 | 273,570 | 733,215 | 18.7M | 12.1M | 13.7M | 12.5M | 12.2M | 10.5M |
| Operating cash flow before change in receivables (USD) | -46,471 | -912,308 | -934,655 | 249,803 | -11.6M | -33.1M | -20.7M | 11.3M | 20.5M | 7.13M |
| Free cash flow (OCF - PPE - intangibles) (USD) | — | — | — | — | — | -33.4M | -27.3M | 8.47M | 16M | 6.41M |
| Income detail | ||||||||||
| Provision for credit losses (USD) | 71,136 | -49,119 | — | — | 133,470 | — | — | — | — | — |
| Credit cost ratio (credit losses / average receivables) (%) | 23.7% | 11.6% | — | — | 35.8% | — | — | — | — | — |
| Reported | May 24, 2017 | Apr 1, 2019 | Apr 1, 2019 | Mar 30, 2020 | Mar 30, 2021 | Mar 22, 2023 | Mar 22, 2023 | Mar 11, 2024 | Mar 10, 2026 | Mar 10, 2026 |
Operating KPIs — quarters
Business figures the company publishes beside its accounts (users, subscribers, same-store sales, production, occupancy ...), read from its results releases and reports, with the growth on the same period a year earlier beneath each: computed from the figures, and as the company states it where it does. Each figure links to its source; counts at a period end show under that period.
| KPI | Jun 26 |
|---|---|
| Paid subscribers YoY growth (company-stated) | +20.0% |
| Reported | Aug 5, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR.
Through an exclusive collaboration with LifeMD, eligible AT&T wireless and fiber customers receive a complimentary LifeMD membership, a $228 annual value, with on-demand access to a nationwide virtual care and pharmacy platform.
Key Takeaways:
● More than 100 million eligible AT&T wireless and fiber customers will receive complimentary access to LifeMD’s virtual care and pharmacy platform.
● The $19-per-month LifeMD membership fee will be fully waived, a value of $228 per year.
● Members can connect with providers for everyday health needs and prescriptions, with many medications shipped directly from LifeMD’s pharmacy.
● The benefit is available through AT&T’s &More program, which allows members to unlock savings and special offers.
What’s the News: AT&T is delivering more value to eligible wireless and fiber customers through an exclusive collaboration with LifeMD, a leading virtual care and pharmacy services provider. Eligible customers receive a complimentary LifeMD membership, connecting them to a nationwide virtual care and pharmacy platform that offers convenient access to healthcare from virtually anywhere.
On August 5, 2026, LifeMD, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.
Regulation FD Disclosure
The Company hereby furnishes an investor presentation (the “Presentation”), which it expects to use in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others commencing on August 5, 2026. The Presentation is furnished herewith as Exhibit 99.2 and may also be found on the Company’s website at https://lifemd.com.
By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this Current Report that is required to be disclosed solely by reason of Regulation FD. The information contained in the Presentation is summary information that is intended to be considered in the context of the Company’s Securities and Exchange Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time to time.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
Company History
Name and ticker changes, and re-registrations under a new regulatory id. When a ticker stopped being used is not recorded, so former tickers are undated.
| Date | Change | Detail |
|---|---|---|
| Feb 25, 2021 | Renamed | CONVERSION LABS, INC. → LIFEMD, INC. |
| Jun 27, 2018 | Renamed | IMMUDYNE, INC. → CONVERSION LABS, INC. |
ETFs Holding LifeMD, Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.